Bristol Advisors’s Pfizer PFE Stock Holding History

Bristol Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-6,535	Closed	-$273K	–	78
2018 Q3	$273K	Buy	+6,535	New	+$252K	0.45%	30
2018 Q1	–	Sell	-16,969	Closed	-$583K	–	73
2017 Q4	$583K	Sell	16,969 -3,373	-17%	-$115K	0.36%	43
2017 Q3	$689K	Buy	20,342 +12,015	+144%	+$386K	0.69%	32
2017 Q2	$265K	Buy	+8,327	New	+$263K	0.18%	40

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bristol Advisors's PFE Position: Q4 2018 in Review

Bristol Advisors sold out of Pfizer (PFE) in Q4 2018, closing a stake of 6,535 shares — an estimated $273K sold.

Bristol Advisors first reported a position in PFE in Q2 2017 and held it in 4 quarters. The position peaked at $689K in Q3 2017. 2,404 funds tracked by Wall St. Rank hold PFE as of Q4 2018.

Bristol Advisors reported no remaining Pfizer position as of Q4 2018 after selling out during the quarter.
Bristol Advisors sold 6,535 Pfizer shares in Q4 2018, an estimated $273K.
Bristol Advisors first reported a position in Pfizer in Q2 2017 and held it in 4 quarters.
Bristol Advisors's Pfizer position peaked at $689K in Q3 2017.
2,404 funds tracked by Wall St. Rank held Pfizer as of Q4 2018.

Based on Bristol Advisors's 13F filing for Q4 2018, filed 14 Jan 2019.